Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Biopsy Gleason pattern 5 tied to recurrence, metastasis, mortality in high-risk prostate cancer

29 Nov 2017

Preoperative biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) subclassification of high-risk prostate cancer identifies men at highest risk for progression, according to a study. Furthermore, any Gleason 5 on biopsy correlates with a higher risk of metastasis, as well as prostate cancer-specific and overall mortality.

The authors assessed men with biopsy Gleason sum 8-10 prostate cancer treated with radical prostatectomy. The patients were divided into those with Gleason 4 + 4 vs those with any pattern 5 (ie, Gleason 3 + 5, 5 + 3, 4 + 5, 5 + 4 or 5 + 5).

Kaplan-Meier, log rank test and Cox proportional hazards models were used to analyse the predictors of biochemical recurrence, metastases, and prostate cancer-specific and overall survival.

A total of 634 men at high risk were identified. Of these, 394 (62 percent) had Gleason 4 + 4 and 240 (38 percent) had Gleason pattern 5 on biopsy. There was no significant difference in baseline characteristics between the groups.

Multivariable analysis revealed that men at high risk with Gleason pattern 5 vs Gleason 4 + 4 had no difference in the risk of biochemical recurrence (hazard ratio [HR], 1.26; 95 percent CI, 0.99 to 1.61; p=0.065). However, patients with any Gleason 5 on biopsy had significantly higher risk for metastasis (HR, 2.55; 1.50 to 4.35; p=0.001), prostate cancer-specific mortality (HR, 2.67; 1.26 to 5.66; p=0.010) and overall mortality (HR, 1.60; 1.09 to 2.34; p=0.016).

“Grouping all Gleason 8-10 tumours together as high-risk lesions may fail to fully stratify men at highest risk for poor outcomes,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.